1138.6000 20.10 (1.80%)
NSE Mar 24, 2026 09:39 AM
Volume: 3,745
 

1138.60
1.80%
ICICI Securities Limited
In FY23, Tatva Chintan (TATVA) earnings were hurt from a downcycle in its SDA business, which should resume growing FY24 onwards. The addition of a significant new customer to its SDA has the potential to propel growth in the near future. PASC segment will likely reap the benefit of products under qualification and long-term growth on the back of a robust pipeline and cleaner chemistry positioning.
Number of FII/FPI investors increased from 31 to 44 in Dec 2025 qtr.
More from Tatva Chintan Pharma Chem Ltd.
Recommended